Ohio-based Venture Therapeutics Named
COLUMBUS, Ohio - The Ohio
State University and the University of Michigan have signed an exclusive
worldwide agreement with Ohio-based Venture Therapeutics, Inc, to form a new
company to develop and commercialize a pharmaceutical technology targeted for
the treatment of precancerous oral lesions. These lesions are currently managed by
invasive surgery and approximately a third of these lesions will reoccur after
published data shows that about 30 percent of the higher grade precancerous oral
lesions progress to oral cancer, specifically oral
squamous cell carcinoma. This type of cancer is particularly devastating to
patients because treatment entails removal of facial and mouth structures
essential for esthetics and function. The National Cancer Institute estimates
that 42,440 Americans will be diagnosed with oral cancer and over 8,390 oral
cancer related deaths will occur in 2014.
The pharmaceutical technology
developed by researchers at The Ohio State University (OSU) College of Dentistry with secondary appointments at the OSU Comprehensive Cancer
Center – Arthur G. James Cancer Hospital and Richard J. Solove Research
– James) and the University of Michigan
addresses a significant unmet need related to the prevention of oral cancer.
Precancerous oral lesions can be seen and touched by patients, so this easy
access to the lesion allows the use of local delivery formulations in an oral
patch to directly treat the disease without causing adverse side effects.
“This type of collaboration,
involving multiple university partners with strong industry support, is
increasingly essential to expedite the discovery, development and delivery of
more targeted cancer therapies. There is no routine cancer, and today it
takes the collective minds across disciplines, institutions and industry to
move the field forward,” says Michael
Caligiuri, MD, director of The Ohio
State University Comprehensive Cancer Center and chief executive officer of the
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
“Ultimately, these collaborations
can be the catalyst for new, more effective cancer treatments, leading to
better outcomes, faster responses, fewer side effects and more hope for cancer
patients everywhere,” said Caligiuri.
These technologies were
developed by a team of university-based researchers who work extensively with
the affected patient population and actively explore new drug delivery methods
such as the oral patch.
R. Mallery , DDS, PhD, professor and interim chair of the division of oral pathology and radiology at the Ohio State
College of Dentistry and member of the OSUCCC – James Molecular Carcinogenesis/Chemoprevention Research Program, worked alongside Steve P. Schwendeman, PhD, Ara G. Paul Professor and Chair of the Department of Pharmaceutical Sciences, Professor of Biomedical Engineering, at the Biointerfaces Institute, University of Michigan, and his former assistant research scientist, Kashappa
Goud Desai, PhD, to invent this breakthrough technology.
“The oral patch sidesteps any toxicity issues, which have historically been a problem with conventional treatments,” said Mallery. “This technology delivers an excellent chemopreventive compound directly to the precancerous tissues.”
Mallery and I have collaborated for years on translational research projects,”
said Schwendeman. “It is very gratifying
to see our efforts progress past the preclinical state and into clinical trials
where we can directly help patients.”
College of Dentistry at Ohio State saw great things for the collaboration
between the two universities. “Having two College
of Dentistry faculty members from Ohio State engage with researchers from the
University of Michigan resulted in a very innovative approach that will
dramatically improve patient care and outcomes,” said Dean Patrick Lloyd,
College of Dentistry. “Conducting the clinical trials for this innovation at
Ohio State’s College of Dentistry is very promising for the technology and
prospective patients, and beneficial to both universities on a national level.”
Drug Development and Commercialization Partnership Formed
Ohio State, through the Ohio State Innovation Foundation and the university’s Drug
Development Institute, and the University of
Michigan licensed the intellectual property to the newly formed Sirona
this unique business model, Ohio State and Venture Therapeutics will work
together throughout the entire drug development process, including
commercialization of the technology. Venture Therapeutics will be responsible
for the drug development activities including formulation development, clinical
trial batch manufacture, clinical trial and bio-analytical activities and regulatory
affairs. Ohio State will provide assistance with transfer of intellectual
property, clinical trials, and recruitment of patients, patient biopsies,
surgical suites, and pharmacokinetic analysis.
“This agreement with Venture
Therapeutics and the creation of Sirona Therapeutics is a
great example of a collaboration that provides long-term value for the
university, central Ohio, and patients,” said Tim Wright, vice president of
Technology Commercialization and Founder of the Drug Development Institute at
Ohio State. “This agreement is in
alignment with one of the university’s research priorities, health and
wellness, with the ultimate goal of moving this technology through
commercialization thereby improving lives.”
Venture Therapeutics, with
offices and laboratories in Columbus and New Albany, was co-founded by Peter
Stoelzle and Michael Medors, who have more than 50 years of combined
experience in the pharmaceutical industry. This alliance will allow continued
faculty participation in the advancement of the technology, as well as
integration of core university facilities during the next phase of human
team of Venture Therapeutics has proven experience in quickly and efficiently
delivering critical care therapeutics to commercial markets. These skill sets
are complementary to Ohio State’s proficiency in the discovery and clinical
development of human therapeutics,” said Stoelzle.
be efficient, given that both Venture Therapeutics and the university are
located in the Central Ohio area. This can help compress development timelines
and enable patients more rapid access to the technology.” said Stoelzle.
About The Ohio State University
Ohio State is a dynamic
community of diverse resources, where opportunity thrives and where individuals
transform themselves and the world. Founded in 1870, The Ohio State University is
a world-class public research university and the leading comprehensive teaching
and research institution in the state of Ohio. With more than 63,000 students
(including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80
centers, and 175 majors, the university offers its students tremendous breadth
and depth of opportunity in the liberal arts, the sciences, and the
About the University of Michigan
The University of Michigan
spends over $1.3 billion per year on its wide-ranging research initiatives,
making it one of the largest, most successful academic research institutions in
the world. U-M Tech Transfer, the University unit responsible for transferring
research discoveries to business and venture partners, launches an average of
10 start-ups, and signs over 100 agreements with businesses annually. More on
U-M Tech Transfer, including an up-to-date list of technologies available for
commercialization, can be found at the U-M Tech Transfer website, http://www.techtransfer.umich.edu.
About The Ohio State University
Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J.
Solove Research Institute
Ohio State’s Comprehensive
Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute (OSUCCC-James) strives to create a cancer-free world by integrating
molecular- and genetic-based discoveries into patient care, a strategy that
leads to better prevention, detection and treatment of individual cancers.
OSUCCC – James is one of only 41 National Cancer Institute-designated
Comprehensive Cancer Centers and one of only four centers funded by the NCI to
conduct both phase I and phase II clinical trials. More than 300 cancer
researchers from 12 of Ohio State’s 14 colleges collaborate across research
programs and disciplines to make some of the world’s most game-changing
discoveries. In December 2014, The Ohio State University will open the doors of
the new James Cancer Hospital and Solove Research Institute, a transformational
facility that fosters collaboration and integration of cancer research and
clinical cancer care. The new James will help revolutionize cancer prevention
and care by enabling world-class oncologists and researchers to work
side-by-side to solve the mysteries of this disease.
About Venture Therapeutics
Therapeutics is a drug development company focused on developing, manufacturing
and delivering innovative human therapies for unmet medical needs. Its
management team has a proven record of success, having received FDA approval
for more than 50 drug products. These products
include injectable, ophthalmic, otic, oral, and topical dosage forms.
Therapeutics, Inc. is a newly formed company among Venture Therapeutics, Inc., Ohio State Innovation Foundation and The
Regents of the University of Michigan created to develop and commercialize a
drug delivery technology to treat precancerous oral lesions.
Contacts: Amanda J. Harper, Director of Media Relations, The
OSUCCC–James, 614-685-5420 (direct), 614-293-3737 (central media line) or Amanda.Harper2@osumc.edu
Melanie Baker, Marketing and
Communications Manager, Ohio State Technology Commercialization Office,
614-292-9839 or email@example.com.